In combination with our previous studies14,15,47, the present data support that miR-155, a negative regulator of eNOS, sGCβ1, and PKG1 in the vasculature, is a common therapeutic target for the development of treatments for atherosclerosis and preeclampsia. This evidence concerns the gene NOS3 and atherosclerosis.